Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zelavespib add-on to ruxolitinib in myelofibrosis
NCT03935555Phase 1Terminated
- Sponsor
- Samus Therapeutics
- Start
- Aug 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zelavespib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF) (4 arms), sponsored by Samus Therapeutics. Primary endpoints: Assess Safety and Tolerability of PU-H71 at 24 weeks, Assess Pharmacokinetics of PU-H71 at 24 weeks and 1 more. Started Aug 2019; status: terminated.
02
Drugs
zelavespib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT03935555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03935555.